Current Drug Delivery, published by Bentham Science Publishers Ltd, serves as a vital platform for advancing the field of pharmaceutical sciences. With an ISSN of 1567-2018 and an E-ISSN of 1875-5704, this esteemed journal focuses on all aspects of drug delivery systems, encompassing innovative research and developments that aim to improve therapeutics and patient outcomes. Operating from the United Arab Emirates, it has an impressive standing reflected in its 2023 Q2 ranking in Pharmaceutical Sciences and a notable position within the 62nd percentile in Scopus’s Pharmacology, Toxicology, and Pharmaceutics category. The journal not only acts as an essential resource for researchers and professionals but it also encourages the dissemination of knowledge among students and budding scientists. With the latest articles and reviews converging from 2004 to 2024, Current Drug Delivery remains committed to offering high-quality content that enhances understanding and sparks innovation in drug delivery mechanisms.

JOURNAL OF NANOBIOTECHNOLOGY is a distinguished academic journal published by BMC in the field of nanobiotechnology, focusing on the intersection of nanoscience, biotechnology, and biomedical engineering. Since its inception in 2003, this open-access journal has played a pivotal role in disseminating high-quality research, becoming a leading platform for innovators and scholars alike. With a remarkable impact factor and consistently ranking in the Q1 category across multiple fields—including Applied Microbiology, Bioengineering, and Pharmaceutical Science—the journal demonstrates its critical relevance and influence in advancing knowledge and applications in nanobiotechnology. Furthermore, its impressive Scopus rankings reflect its commitment to rigorously peer-reviewed content, making it a go-to resource for researchers, professionals, and students striving to push the boundaries of science. Given its broad scope, covering emerging trends and technologies, JOURNAL OF NANOBIOTECHNOLOGY continues to foster collaboration and innovation across multidisciplinary fields, inviting submissions from across the globe.

DRUG DELIVERY is a premier academic journal published by TAYLOR & FRANCIS LTD, with a steadfast commitment to advancing research in the fields of medicine and pharmaceutical sciences. As an Open Access journal since 2017, it offers unparalleled accessibility to its high-quality content, making it an invaluable resource for researchers, professionals, and students alike. With an impressive 2023 impact factor, it ranks in the Q1 quartile for both Medicine (miscellaneous) and Pharmaceutical Science, evidencing its significant impact within the scientific community. The journal focuses on innovative drug delivery systems, therapeutics, and methodologies that enhance patient care and treatment options. Based in the United Kingdom, it has evolved since its inception in 1993 to create a richly diverse platform for scholarly dialogue and advancements in the pharmaceutical landscape. Researchers looking to stay at the forefront of drug delivery research will find DRUG DELIVERY an essential companion in their pursuits.

Journal of Pharmaceutical Investigation, published by SPRINGERNATURE, is a leading academic resource in the field of pharmaceutical sciences, offering critical insights and innovative research findings. With an impact factor that underscores its significance, this journal ranks in the Q1 category for both Pharmacology and Pharmaceutical Science as of 2023, showcasing its high-quality publications and rigorous peer-review processes. Operating from the Netherlands, the journal spans from 2012 to 2024, offering a rich archive of interdisciplinary research contributions that advance knowledge in pharmacology, toxicology, and pharmaceutics. It holds impressive Scopus rankings, placing it among the top-tier journals in its categories, which enhances its appeal to researchers, professionals, and students aiming to publish their work or stay up-to-date with the latest advancements in the pharmaceutical field. Engaging with the Journal of Pharmaceutical Investigation not only enriches your understanding but also connects you with a community dedicated to advancing healthcare and therapeutic innovations.

The International Journal of Pharmaceutics, a prestigious publication from ELSEVIER, stands at the forefront of the pharmaceutical science field, exemplified by its impressive ranking of #15 out of 183 in Pharmacology, Toxicology, and Pharmaceutics, placing it in the 92nd percentile. Established in 1978, this journal has continuously provided a platform for researchers, professionals, and students to share groundbreaking discoveries and innovations in drug formulation, delivery systems, and pharmacokinetics. With a Q1 ranking in the 2023 category of Pharmaceutical Science, it underscores its significance in disseminating high-quality research that shapes clinical practices and enhances therapeutic outcomes. While the journal does not currently offer open access options, it remains accessible to subscribers through its publication based in Amsterdam, Netherlands, ensuring a broad reach within the scientific community. As it converges towards a vibrant future, the International Journal of Pharmaceutics continues to be an essential resource for anyone dedicated to advancing the field of pharmacy and drug development.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

BIOMATERIALS, published by Elsevier Science Ltd, is a premier academic journal dedicated to the interdisciplinary field of biomaterials research. With an impressive impact factor, it ranks in the Q1 quartile across multiple categories including Bioengineering, Biomaterials, and Biophysics, showcasing its significance in advancing scientific knowledge. Established in 1980 and set to converge its discussions through 2025, this journal provides a critical platform for researchers and professionals to disseminate their findings on the development, application, and performance of biomaterials. The journal covers a wide range of topics, from the mechanics of materials to nanotechnology, and is highly regarded with top Scopus rankings in essential categories, including an exceptional position within the 99th percentile for Biophysics. Although not an open access journal, BIOMATERIALS remains vital for students and established researchers alike, ensuring accessibility to groundbreaking research in the field. Engage with cutting-edge studies that pave the way for innovative applications in medicine, engineering, and beyond.